CA2776278A1 - Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors - Google Patents
Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors Download PDFInfo
- Publication number
- CA2776278A1 CA2776278A1 CA2776278A CA2776278A CA2776278A1 CA 2776278 A1 CA2776278 A1 CA 2776278A1 CA 2776278 A CA2776278 A CA 2776278A CA 2776278 A CA2776278 A CA 2776278A CA 2776278 A1 CA2776278 A1 CA 2776278A1
- Authority
- CA
- Canada
- Prior art keywords
- level
- inhibitor
- polypeptide
- akt
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G01N33/575—
-
- G01N33/57515—
-
- G01N33/57555—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24827009P | 2009-10-02 | 2009-10-02 | |
| US61/248,270 | 2009-10-02 | ||
| US25580509P | 2009-10-28 | 2009-10-28 | |
| US61/255,805 | 2009-10-28 | ||
| US32377110P | 2010-04-13 | 2010-04-13 | |
| US61/323,771 | 2010-04-13 | ||
| US38068510P | 2010-09-07 | 2010-09-07 | |
| US61/380,685 | 2010-09-07 | ||
| PCT/US2010/051341 WO2011041785A1 (en) | 2009-10-02 | 2010-10-04 | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2776278A1 true CA2776278A1 (en) | 2011-04-07 |
Family
ID=43128291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2776278A Abandoned CA2776278A1 (en) | 2009-10-02 | 2010-10-04 | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110212845A1 (enExample) |
| EP (1) | EP2483686A1 (enExample) |
| JP (1) | JP2013506836A (enExample) |
| KR (1) | KR20120104196A (enExample) |
| AU (1) | AU2010300307A1 (enExample) |
| BR (1) | BR112012007555B1 (enExample) |
| CA (1) | CA2776278A1 (enExample) |
| IL (1) | IL218935A0 (enExample) |
| IN (1) | IN2012DN03817A (enExample) |
| MX (1) | MX2012003997A (enExample) |
| WO (1) | WO2011041785A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212773D0 (en) * | 2012-07-18 | 2012-08-29 | Ucl Business Plc | Vascular remodelling |
| US9146545B2 (en) | 2012-11-27 | 2015-09-29 | Honeywell International Inc. | Multivariable control system for setpoint design |
| TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
| KR101593595B1 (ko) * | 2013-10-08 | 2016-02-12 | 한국생명공학연구원 | Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제 |
| WO2015053452A1 (ko) * | 2013-10-08 | 2015-04-16 | 한국생명공학연구원 | Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제 |
| US20170051062A1 (en) * | 2014-02-18 | 2017-02-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway |
| MX375557B (es) * | 2014-07-18 | 2025-03-06 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer. |
| WO2016133860A1 (en) * | 2015-02-16 | 2016-08-25 | Board Of Regents Of The University Of Nebraska | Cancer biomarkers and methods of use thereof |
| GB202102895D0 (en) * | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2023190820A1 (ja) * | 2022-03-30 | 2023-10-05 | 公立大学法人福島県立医科大学 | 抗CK2α抗体又はその断片 |
| CN115160341B (zh) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
| KR102641010B1 (ko) * | 2023-12-04 | 2024-02-28 | 대한민국 | 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200715636A (en) | 2005-10-04 | 2007-04-16 | Antig Tech Co Ltd | Method of controlling fuel concentration used in direct liquid fuel cell |
| ES2528316T3 (es) | 2006-09-01 | 2015-02-06 | Senhwa Biosciences, Inc. | Moduladores de la serina-treonina proteína quinasa y de PARP |
| US8488289B2 (en) | 2006-09-27 | 2013-07-16 | International Rectifier Corporation | Current protection circuit for intelligent power switch |
| US20090035609A1 (en) | 2007-07-31 | 2009-02-05 | Apple Inc. | Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices |
-
2010
- 2010-10-04 WO PCT/US2010/051341 patent/WO2011041785A1/en not_active Ceased
- 2010-10-04 AU AU2010300307A patent/AU2010300307A1/en not_active Abandoned
- 2010-10-04 IN IN3817DEN2012 patent/IN2012DN03817A/en unknown
- 2010-10-04 EP EP10765546A patent/EP2483686A1/en not_active Withdrawn
- 2010-10-04 BR BR112012007555-1A patent/BR112012007555B1/pt active IP Right Grant
- 2010-10-04 JP JP2012532136A patent/JP2013506836A/ja active Pending
- 2010-10-04 KR KR1020127011401A patent/KR20120104196A/ko not_active Withdrawn
- 2010-10-04 CA CA2776278A patent/CA2776278A1/en not_active Abandoned
- 2010-10-04 US US12/897,640 patent/US20110212845A1/en not_active Abandoned
- 2010-10-04 MX MX2012003997A patent/MX2012003997A/es not_active Application Discontinuation
-
2012
- 2012-03-29 IL IL218935A patent/IL218935A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN03817A (enExample) | 2015-08-28 |
| JP2013506836A (ja) | 2013-02-28 |
| BR112012007555B1 (pt) | 2020-09-29 |
| IL218935A0 (en) | 2012-07-31 |
| US20110212845A1 (en) | 2011-09-01 |
| WO2011041785A1 (en) | 2011-04-07 |
| BR112012007555A2 (pt) | 2016-10-25 |
| MX2012003997A (es) | 2012-07-25 |
| EP2483686A1 (en) | 2012-08-08 |
| KR20120104196A (ko) | 2012-09-20 |
| AU2010300307A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110212845A1 (en) | Biomarkers for predicting the sensitivity and response of protein kinase CK2-mediated diseases to CK2 Inhibitors | |
| US20240325398A1 (en) | Combination therapies | |
| ES2787073T3 (es) | Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa | |
| KR101909801B1 (ko) | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 | |
| CN114375192A (zh) | 鉴定smarca2/4降解剂的应答者的方法 | |
| US20110065712A1 (en) | Tricyclic compounds and pharmaceutical uses thereof | |
| US20120129849A1 (en) | Deuterated serine-threonine protein kinase modulators | |
| WO2011011199A1 (en) | Combination therapies with ck2 modulators | |
| KR20120104180A (ko) | 신규한 트리시클릭 단백질 키나제 조절제 | |
| WO2012006589A2 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| CN105611940A (zh) | 诊断方法和用于治疗成胶质细胞瘤的组合物 | |
| EP4376886A2 (en) | Methods of treating cancer | |
| WO2012170827A2 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| WO2018161081A1 (en) | Gene signatures to predict drug response in cancer | |
| TW202214248A (zh) | 使用mdm2拮抗劑的癌症療法之生物標記 | |
| KR20250048049A (ko) | 암의 치료에 사용하기 위한 mta-협동적 prmt5 억제제 | |
| CN118043053A (zh) | 治疗癌症的方法 | |
| EP2999966B1 (en) | Methods for predicting and improving the survival of colorectal cancer patients | |
| HK1263276A1 (en) | Method for selecting a therapy for the treatment of colorectal cancer patients | |
| HK1223156B (en) | Methods for predicting and improving the survival of colorectal cancer patients | |
| HK1230250A1 (en) | Diagnostic methods and compositions for treatment of glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20131004 |